首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1549989

輕度認知障礙的全球市場:疾病類型·年齡·適應症·治療方法·不同地區的預測 (～2032年)

Global Mild Cognitive Impairment Market Research Report By Disease Type, By Age, By Indication, By Treatment, And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032

出版日期: 2024年08月28日 | 出版商:

Market Research Future | 英文 153 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

輕度認知障礙市場規模預計到 2032 年為 32.5 億美元，預測期內複合年增長率為 5.95，從 2023 年的 19.4 億美元和 2024 年的 20.5 億美元增長到 2032 年。

輕度認知障礙市場的主要推動因素是全球範圍內輕度認知障礙的盛行率不斷上升以及人們對輕度認知障礙的認識不斷增強。儘管輕度認知障礙早期診斷的技術發展預計將帶來利潤豐厚的市場前景，但多種藥物和合併症的控制使治療方案變得複雜，預計也會減緩全球市場的成長。

區域見解

北美市場在 2022 年佔據最大市場佔有率，為 42.60%，預計在預測期內複合年增長率為 4.97%，到 2032 年達到約 13.1 億美元的規模。此外，預計亞太地區在預測期內將以 6.91% 的複合年增長率增長最快。預計未來北美輕度認知障礙市場將穩定成長。對醫療基礎設施的投資和對現代醫療解決方案認識的提高預計將進一步推動市場成長。現有企業和新進業者都準備好透過改進技術來利用這一潛力，以滿足對更好手術結果日益增長的需求。

由於技術進步、醫療成本上升以及輕度認知障礙負擔增加，歐洲市場佔據第二大市場。德國預計將擁有最大的市場佔有率，而英國預計將成為歐洲成長最快的國家。

本報告調查了全球輕度認知障礙市場，提供了市場的定義和概述，分析了市場成長的各種影響因素、市場規模的趨勢和預測、各個細分市場和地區的細分以及競爭。

Global Mild Cognitive Impairment Market Research Report By Disease Type (Amnestic MCI and Non-Amnestic MCI), By Age (Child, Adult, Geriatric), By Indication (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, and Others) By Treatment (Medication (Cholinesterase Inhibitors, Benzodiazepines, Glutamate Inhibitors, Antihistamines, Mao Inhibitors, Proton Pump Inhibitors, and Others), Therapy (Cognitive Stimulation Therapy, Cognitive Behavioural Therapy (CBT)), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World - Forecast Till 2032

Market Overview

The market size for mild cognitive impairment was estimated to be USD 1.94 billion in 2023. The global mild cognitive impairment industry is expected to expand from USD 2.05 billion in 2024 to USD 3.25 billion by 2032, with a compound annual growth rate (CAGR) of 5.95% during the forecast period (2024-2032).

The growing prevalence of mild cognitive impairment around the world, as well as increased awareness of mild cognitive impairment, are the primary drivers of the Mild Cognitive Impairment Market. However, polypharmacy and controlling comorbidities complicate treatment options, which is projected to slow worldwide market growth. Nonetheless, technological developments in the early diagnosis of MCI around the world are expected to provide profitable market prospects. The rising global prevalence of moderate cognitive impairment (MCI) is a primary driver of the global MCI treatment industry.

Marketing Segmentation

Mild Cognitive Impairment Market Segmentation by Disease Type, Amnestic MCI, and Non-Amnestic MCI.

The mild cognitive impairment market segmentation by age comprises child, adult, and geriatric.

The Mild Cognitive Impairment Market has been classified according to indication: Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and others.

The Mild Cognitive Impairment Market has been divided into two segments: medicine and therapy.

Regional insights

The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American mild cognitive impairment market had the greatest market share of 42.60% in 2022 and is expected to reach roughly USD 01.31 billion by 2032, growing at a 4.97% CAGR over the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 6.91% over the forecast period. The North American mild cognitive impairment market is expected to increase steadily in the future. Investments in healthcare infrastructure and increased awareness of modern medical solutions are projected to propel market growth even further. Both established firms and new entrants are ready to seize these possibilities, utilizing technological improvements to address the growing need for better surgical outcomes.

Europe's mild cognitive impairment market accounted for the second-largest market share due to technological improvements, rising healthcare costs, and an increased burden of mild cognitive impairment. Furthermore, the German mild cognitive impairment market is expected to have the biggest market share, with the UK mild cognitive impairment market forecast to be the fastest expanding market in Europe.

The Asia-Pacific mild cognitive impairment market is predicted to develop the fastest from 2024 to 2032, owing to a large patient population, an increasing number of mild cognitive cases, and favorable regulatory regulations. Furthermore, prominent companies in the mild cognitive impairment market are aggressively expanding into this region, propelling the regional market forward. Furthermore, China's mild cognitive impairment market had the greatest market share, while India's mild cognitive impairment market is expected to be the fastest expanding in the Asia-Pacific region.

Major Players

Key players in the mild cognitive impairment market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), AbbVie Inc. (US), Biogen (Switzerland), Eisai Co., Ltd. (Japan), Aurobindo Pharma (India), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), and Taj Pharmaceuticals Limited (India).

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research DATA FLOW:
- 3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
- 3.7.1 Data forecasting Technique
3.8 DATA MODELLING
- 3.8.1 Microeconomic Factor Analysis:
- 3.8.2 Data MODELLING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 Increasing burden of Mild cognitive impairment across the globe
- 4.2.2 Rising awareness associated with mild cognitive impairment
4.3 RESTRAINTS
- 4.3.1 Polypharmacy and managing comorbidities complicate treatment strategies
4.4 OPPORTUNITY
- 4.4.1 Technological advancements for early diagnosis of MCI

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 Threat of New Entrants
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 Threat of Substitutes
- 5.1.4 Bargaining Power of Buyers
- 5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GLOBAL MILD COGNITIVE IMPAIRMENT MARKET

6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE

6.1 OVERVIEW
6.2 AMNESTIC MCI
6.3 NON-AMNESTIC MCI

7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE

7.1 OVERVIEW
7.2 CHILD
7.3 ADULT
7.4 GERIATRIC

8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION

8.1 OVERVIEW
8.2 LEWY BODY DEMENTIA
8.3 PARKINSON'S DISEASE DEMENTIA
8.4 ALZHEIMER'S DISEASE
8.5 VASCULAR DEMENTIA
8.6 OTHERS

9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT

9.1 OVERVIEW
9.2 MEDICATION
- 9.2.1 Cholinesterase Inhibitors
- 9.2.2 Benzodiazepines
- 9.2.3 Glutamate Inhibitors
- 9.2.4 Antihistamines
- 9.2.5 Mao Inhibitors
- 9.2.6 Proton Pump Inhibitors
- 9.2.7 Others
9.3 THERAPY
- 9.3.1 Cognitive Stimulation Therapy
- 9.3.2 Cognitive Behavioural Therapy (CBT)

10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 us
- 10.2.2 canada
10.3 EUROPE
- 10.3.1 Germany
- 10.3.2 France
- 10.3.3 UK
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 ASIA-PACIFIC
- 10.4.1 China
- 10.4.2 India
- 10.4.3 Japan
- 10.4.4 South Korea
- 10.4.5 AUSTRALIA
- 10.4.6 Rest of Asia-Pacific
10.5 REST OF THE WORLD
- 10.5.1 Middle East & Africa
- 10.5.2 Latin America

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS,
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 product launch / Product approval

12 COMPANY PROFILES

12.1 JOHNSON & JOHNSON SERVICES, INC
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 productS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 PFIZER INC
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 productS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
12.3 NOVARTIS AG
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 productS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
12.4 ABBVIE INC.
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
12.5 BIOGEN
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
12.6 EISAI CO., LTD.
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 KEY STRATEGIES
12.7 AUROBINDO PHARMA
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 KEY STRATEGIES
12.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
12.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 TAJ PHARMACEUTICALS LTD.
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

13 DATA CITATIONS

簡介目錄圖表

LIST OF TABLES

TABLE 1 QFD MODELLING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR AMNESTIC MCI, BY REGION, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR NON-AMNESTIC MCI, BY REGION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR CHILD, BY REGION, 2019-2032 (USD BILLION)
TABLE 7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR ADULT, BY REGION, 2019-2032 (USD BILLION)
TABLE 8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR GERIATRIC, BY REGION, 2019-2032 (USD BILLION)
TABLE 9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR LEWY BODY DEMENTIA, BY REGION, 2019-2032 (USD BILLION)
TABLE 11 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR PARKINSON'S DISEASE DEMENTIA, BY REGION, 2019-2032 (USD BILLION)
TABLE 12 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR ALZHEIMER'S DISEASE, BY REGION, 2019-2032 (USD BILLION)
TABLE 13 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR VASCULAR DEMENTIA, BY REGION, 2019-2032 (USD BILLION)
TABLE 14 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
TABLE 15 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 16 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY REGION, 2019-2032 (USD BILLION)
TABLE 17 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 18 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR CHOLINESTERASE INHIBITORS, BY REGION, 2019-2032 (USD BILLION)
TABLE 19 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR BENZODIAZEPINES, BY REGION, 2019-2032 (USD BILLION)
TABLE 20 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR GLUTAMATE INHIBITORS, BY REGION, 2019-2032 (USD BILLION)
TABLE 21 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR ANTIHISTAMINES, BY REGION, 2019-2032 (USD BILLION)
TABLE 22 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR MAO INHIBITORS, BY REGION, 2019-2032 (USD BILLION)
TABLE 23 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR PROTON PUMP INHIBITORS, BY REGION, 2019-2032 (USD BILLION)
TABLE 24 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
TABLE 25 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY REGION, 2019-2032 (USD BILLION)
TABLE 26 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 27 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR COGNITIVE STIMULATION THERAPY, BY REGION, 2019-2032 (USD BILLION)
TABLE 28 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR COGNITIVE BEHAVIOURAL THERAPY (CBT), BY REGION, 2019-2032 (USD BILLION)
TABLE 29 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION, 2019-2032 (USD BILLION)
TABLE 30 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 31 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 32 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 33 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 34 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 35 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 36 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 37 US MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 38 US MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 39 US MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 40 US MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 41 US MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 42 US MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 43 CANADA MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 44 CANADA MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 45 CANADA MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 46 CANADA MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 47 CANADA MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 48 CANADA MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 49 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 50 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 51 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 52 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 53 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 54 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 55 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 56 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 57 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 58 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 59 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 60 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 61 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 62 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 63 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 64 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 65 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 66 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 67 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 68 UK MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 69 UK MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 70 UK MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 71 UK MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 72 UK MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 73 UK MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 74 ITALY MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 75 ITALY MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 76 ITALY MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 77 ITALY MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 78 ITALY MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 79 ITALY MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 80 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 81 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 82 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 83 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 84 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 85 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 86 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 87 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 88 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 89 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 90 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 91 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 92 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 93 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 94 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 95 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 96 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 97 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 98 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 99 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 100 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 101 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 102 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 103 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 104 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 105 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 106 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 107 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 108 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 109 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 110 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 111 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 112 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 113 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 114 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 115 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 116 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 117 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 118 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 119 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 120 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 121 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 122 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 123 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 124 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 125 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 126 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 127 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 128 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 129 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 130 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 131 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 132 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 133 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 134 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 135 REST OT THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY REGION, 2019-2032 (USD BILLION)
TABLE 136 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 137 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 138 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 139 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 140 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 141 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 142 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 143 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 144 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 145 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 146 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 147 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 148 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 149 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 150 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 151 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 152 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 153 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 154 PUBLIC PLAYERS STOCK SUMMARY
TABLE 155 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 156 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 157 JOHNSON & JOHNSON SERVICES, INC: PRODUCT OFFERED
TABLE 158 PFIZER INC: PRODUCT OFFERED
TABLE 159 NOVARTIS AG: PRODUCT OFFERED
TABLE 160 ABBVIE INC.: PRODUCTS OFFERED
TABLE 161 BIOGEN: PRODUCTS OFFERED
TABLE 162 BIOGEN: KEY DEVELOPMENTS
TABLE 163 EISAI CO., LTD.: PRODCUTS OFFERED
TABLE 164 EISAI CO., LTD.: KEY DEVELOPMENTS
TABLE 165 AUROBINDO PHARMA: PRODCUTS OFFERED
TABLE 166 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 167 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODCUTS OFFERED
TABLE 168 TAJ PHARMACEUTICALS LTD.: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET: STRUCTURE
FIGURE 2 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL MILD COGNITIVE IMPAIRMENT MARKET
FIGURE 6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2022 & 2032 (USD BILLION)
FIGURE 7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY DISEASE TYPE,
FIGURE 8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2022 & 2032 (USD BILLION)
FIGURE 9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY AGE,
FIGURE 10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2022 & 2032 (USD BILLION)
FIGURE 11 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY INDICATION,
FIGURE 12 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2022 & 2032 (USD BILLION)
FIGURE 13 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY TREATMENT,
FIGURE 14 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION, 2022 & 2032 (USD BILLION)
FIGURE 15 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY REGION,
FIGURE 16 NORTH AMERICA MARKET ANALYSIS: MILD COGNITIVE IMPAIRMENT MARKET, 2019-2032 (USD BILLION)
FIGURE 17 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
FIGURE 18 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY COUNTRY,
FIGURE 19 EUROPE MARKET ANALYSIS: MILD COGNITIVE IMPAIRMENT MARKET, 2019-2032 (USD BILLION)
FIGURE 20 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
FIGURE 21 EUROPE MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY COUNTRY,
FIGURE 22 ASIA-PACIFIC MARKET ANALYSIS: MILD COGNITIVE IMPAIRMENT MARKET, 2019-2030 (USD BILLION)
FIGURE 23 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2022 & 2030 (USD BILLION)
FIGURE 24 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY COUNTRY,
FIGURE 25 REST OF THE WORLD MARKET ANALYSIS: MILD COGNITIVE IMPAIRMENT MARKET, 2019-2030 (USD BILLION)
FIGURE 26 REST OT THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY REGION, 2022 & 2030 (USD BILLION)
FIGURE 27 REST OT THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY REGION,
FIGURE 28 MILD COGNITIVE IMPAIRMENT MARKET PLAYERS: COMPETITIVE ANALSIS,
FIGURE 29 COMPETITOR DASHBOARD: GLOBAL MILD COGNITIVE IMPAIRMENT MARKET
FIGURE 30 JOHNSON & JOHNSON SERVICES, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 JOHNSON & JOHNSON SERVICES, INC: SWOT ANALYSIS
FIGURE 32 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 PFIZER INC: SWOT ANALYSIS
FIGURE 34 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 NOVARTIS AG: SWOT ANALYSIS
FIGURE 36 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 ABBVIE INC.: SWOT ANALYSIS
FIGURE 38 BIOGEN: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 EISAI CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 AUROBINDO PHARMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 41 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW
FIGURE 42 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 43 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT